Annual Report 2017 - 2018

“Prior to the PBS listing of the direct-acting antivirals the number of people progressing to liver cancer or dying as a consequence of their hepatitis C infection was rising each year. Since then the tide has turned due to the high uptake of treatment among those with hepatitis C related cirrhosis. For the first time in many years we have seen small decreases in new cases of liver cancer and hepatitis C-related deaths.” Extract from Presidents Message (p14)

Download a copy of this Annual Report

Annual Report 2016 - 2017

"Elimination is the word that has been on everyone’s lips this year and there are  undoubtedly unprecedented opportunities to act decisively to end the hepatitis B and hepatitis C epidemics in Australia by 2030, in line with the World Health Organization’s global targets." CEO and President's Message (p11)

Download a copy of this Annual Report

Annual Report 2015 - 2016

"During 2015 to 2016 much of our work was associated with advocacy for universal access to the new hepatitis C medications, as well as preparing for the changes to treatment and responding to system issues arising during the first few months of the rollout." - Highlights from 2015-2016 (p12)

Download a copy of this Annual Report